Abstract
Abstract Background. Burkitt’s Lymphoma (BL) has three peaks of occurrence, in children, adults and elderly, at 10, 40 and 70 years respectively. To the best of our knowledge, no study has been conducted to assess predictors of survival in the three age groups. We hypothesized that the predictors of survival may differ by age group. We, therefore, sought to determine the predictors of survival for BL in these three groups: children (<15 years of age), adults (40-70 years of age) and elderly (>70 years of age). Methods. Using the Surveillance, Epidemiology, and End Results (SEER) database covering the years 2000-2013, we identified 797 children, 1,994 adults and 757 elderly patients newly diagnosed with BL. We used Cox proportional hazards regression models to determine prognostic factors for survival for each age group. Results. Five-year relative survival in BL for children, adults and elderly were 90.4%, 47.8%, and 28.9%, respectively. Having at least stage II disease and multiple primaries were associated with higher mortality in the elderly group. In adults, multiple primaries, stage III or IV disease, African American race and bone marrow primary were associated with increased mortality whereas stage IV disease and multiple primaries were associated with worse outcome in children. Conclusion. These findings demonstrate commonalities and differences in predictors of survival that may have implications for management of BL patients. Financial Support: This work was supported by the US National Institutes of Health/National Cancer Institute 1P20CA210300-01 (PI: Shu XO, Tran T/Sub-contract-PI: Luu HN) and the University of South Florida start-up grant (PI: Luu HN). Note: This abstract was not presented at the meeting. Citation Format: Fahad Mukhtar, Paolo Boffetta, Harvey A. Risch, Jong Y. Park, Omonigho M. Bubu, Lindsay Womack, Thuan V. Tran, Janice C. Zgibor, Hung N. Luu. Survival predictors of Burkitt's lymphoma in children, adults and elderly in the United States during 2000-2013 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3297. doi:10.1158/1538-7445.AM2017-3297
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
